ClinicalTrials.gg
CompletedNCT00704730EXAMUpdated Apr 20, 2021Results posted

Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer

A Phase 3 interventional study of XL184 and Placebo in Thyroid Cancer, sponsored by Exelixis. Completed at 114 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-20.

Sponsored by Exelixis · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
330
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing cabozantinib in Thyroid Neoplasms — 1 open to participants now, 4 under way, 1 of them phase 3. cabozantinib · Thyroid Neoplasms.

Enrollment
2nd of 10
330 · median 64
Started
2008
the only one that year
Phase 3
2 of 10
none open now
Registered
2nd of 10
by date
Lead sponsor
4 of 10
Exelixis

Among the 10 studies testing cabozantinib in Thyroid Neoplasms, this one is the 2nd largest by enrollment, is the only one that started in 2008, is one of 2 in phase 3, and was the 2nd registered.

Thyroid Neoplasms

785 studies on the registry are indexed under Thyroid Neoplasms; 204 are open to participants now.

Browse Thyroid Neoplasms studies →

Open to participants now

1 of the 10 studies testing cabozantinib in Thyroid Neoplasms is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About cabozantinib

cabozantinib: first FDA approval 2012 (COMETRIQ), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 152 Thyroid Neoplasms studies recruiting now, 96 (63%) set no upper age limit and 27 (18%) stop at 75 or younger; 37 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing cabozantinib in Thyroid Neoplasms, or all of them as a file.
02

Study summary

The purpose of this research study is to evaluate the progression-free survival (PFS) with XL184 as compared with placebo (an inactive substance) in subjects with unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC). Subjects will be randomized to receive XL184 or placebo in a 2:1 ratio. XL184 is an investigational drug that inhibits VEGFR2, MET and RET, kinases implicated in tumor formation, growth and migration.

The Clinical Steering Committee for this study, comprised of study doctors who specialize in medullary thyroid cancer, has provided guidance regarding the design of the study. The committee includes: Douglas Ball, MD, Barry Nelkin, PhD, Martin Schlumberger, MD and Steven Sherman, MD.

03

Conditions studied

  • Thyroid Cancer

Keywords

  • Medullary Thyroid Cancer
  • MTC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject has a confirmed diagnosis of MTC that cannot be removed by surgery, is locally advanced, or has spread in the body.
  • The subject is at least 18 years old.
  • The subject has an (Eastern Cooperative Oncology Group) performance status ≤ 2.
  • The subject has documented worsening of disease (progressive disease) at screening compared with a previous CT scan or MRI image done within 14 months of screening.
  • The subject has recovered from adverse events (side effects) due to any other medications that were administered prior to randomization.
  • The subject has adequate organ and bone marrow function.
  • Subjects who are sexually active (male and female) must agree to use medically accepted methods of during the course of the study and for 3 months following discontinuation of study treatments.
  • The subject has no other diagnosis of cancer (unless non-melanoma skin cancer, an early form of cervical cancer, or another cancer diagnosed ≥ 2 years previously) and currently has no evidence of (unless non-melanoma skin cancer or an early form of cervical cancer).
  • Female subjects of must have a negative pregnancy test at screening.

Exclusion criteria

Exclusion Criteria:

  • The subject has received prior treatment for their cancer within 4 weeks of randomization (6 weeks for nitrosoureas or mitomycin C).
  • The subject has received radiation to ≥ 25 % of bone marrow.
  • The subject has received treatment with other agents (unapproved therapies) within 4 weeks of randomization.
  • The subject has received treatment with XL184.
  • The subject has or spinal cord compression, unless completed radiation therapy ≥ 4 weeks prior to randomization and stable without and without anti-convulsant treatment for ≥ 10 days.
  • The subject has a history of episodes of vomiting blood or a recent history of vomiting > 2.5 mL (about 1/2 teaspoon) of red blood.
  • The subject has serious illness other than cancer.
  • The subject is pregnant or breastfeeding.
  • The subject has an active infection requiring ongoing treatment.
  • The subject is incapable of understanding and complying with the protocol or unable to provide .
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
330 participants (actual)

Study arms

  • Experimental
    1

    Drug: XL184

  • Placebo comparator
    2

    Drug: Placebo

Interventions

  • DrugXL184

    Gelatin capsules supplied in 25-mg and 100-mg strengths administered orally daily

  • DrugPlacebo

    Gelatin capsules color and size-matched to XL184 capsules administered orally daily

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    The duration of Progression-Free Survival (PFS) using progression events as determined by Independent Review Committee (IRC) per mRECIST, or death due to any cause. The analysis was conducted after at least 315 subjects were randomized and at least 138 events were observed.

    Time frame: Treatment period consisted of 4-week cycles with radiologic tumor assessment every 12 weeks from date of randomization until date of first documented PD or date of death from any cause, whichever came first, assessed up to 34 months.

Secondary outcomes

  1. Overall Survival (OS) With XL184 Compared With Placebo

    Duration of Overall Survival (OS) from the time of randomization to death due to any cause. A Kaplan-Meier analysis was performed to estimate the median.

    Time frame: The pre-specified interim analysis of Overall Survival (OS) was assessed at 44% of required events. Includes data up to 15June2011. As of this date, the number of deaths required to conduct the primary analysis had not been reached.

  2. Objective Response Rate (ORR)

    The proportion of subjects with a best overall response (BOR) of confirmed complete response (CR) or partial response (PR) as determined by the Independent Review Committee (IRC.) Per Response Evaluation Criteria in Solid Tumor Criteria (mRECIST v1.0) for target lesions and assessed by MRI or CT: Complete Response (CR) disappearance of all target lesions; Partial Response (PR) ≥ 30% decrease in the sum of the longest diameter of target lesions; Progressive Disease (PD) ≥ 20% increase in the sum of the longest diameter of target lesions. Overall Response Rate: ORR=CR +PR

    Time frame: Assessed at the same time as primary analysis of Progression Free Survival (PFS) data. Assessed at baseline and every 12 weeks until Progressive Disease (PD) up to 34 months.

  3. Duration of Objective Response (OR): Independent Radiology Committee (IRC) Determined

    For those subjects with Independent Radiology Committee (IRC) determined Objective Response Rate (ORR), the amount of time from documentation of Objective Response (OR) until Progressive Disease (PD) by mRECIST or death due to any cause.

    Time frame: From time of first documentation of Objective Response (OR), confirmed at a later visit ≥28 days later as Progressive Disease (PD) as defined by mRECIST or death due to any cause, assessed up to 34 months.

  4. Biochemical Response Calcitonin (CTN) %

    For each on-treatment tumor marker assessment from each subject, the biochemical response of CTN was determined based on percent increase or decrease from baseline. Best biochemical response over course of treatment was determined from evaluation of subject's time point response data. Biochemical response criteria: Complete Response (CR) - decrease in tumor marker into normal range from baseline value; Partial Response (PR) - decrease of \>50% from baseline value when baseline value is above normal range; Stable Disease (SD) - no more than a 50% increase and no more than a 50% decrease from baseline value above normal range; Progressive Disease (PD) - increase of \>50% from baseline value when baseline value is above normal range / or increase from low or normal range at baseline to above normal range; Not Evaluable (NE) - missing baseline value / or baseline value is not elevated and response is not PD / or response can not be determined due to change in assay format.

    Time frame: Serum tumor markers CTN evaluated from blood samples collected at screening and every 12 weeks (±5 days from randomization) until date of first documented progression or date of death from any cause, whichever came first, assessed for up to 34 months.

  5. Biochemical Response Carcinoembryonic Antigen (CEA) %

    For each on-treatment tumor marker assessment from each subject, the biochemical response of CEA was determined based on percent increase or decrease from baseline. Best biochemical response over the course of treatment was determined from evaluation of each subject's time point response data. Biochemical response: Complete Response (CR)- Decrease in tumor marker into normal range from baseline value; Partial Response (PR)- Decrease of \>50% from baseline value when baseline value is above normal range; Stable Disease (SD)- No more than a 50% increase and no more than a 50% decrease from baseline value above normal range; Progressive Disease (PD)- Increase of \>50% from baseline value when baseline value is above normal range / or increase from low or normal range at baseline to above normal range; Not Evaluable (NE)- Missing baseline value / or baseline value is not elevated and response is not Progressive Disease (PD) / or response can not be determined due to change in assay format.

    Time frame: Serum tumor markers CEA evaluated from blood samples collected at screening and every 12 weeks (± 5 days from randomization) until date of first documented progression or date of death from any cause, whichever came first, assessed for up to 34 months.

07

Results

Posted Sep 9, 2014

Participant flow

First patient enrolled 10 September 2008, last patient enrolled 27 February 2011. Data cut off date 15 June 2011.

Participant flow — Overall Study
MilestoneXL184 (Cabozantinib)Placebo
Started219111
Completed9815
Not completed12196
Withdrew: Adverse event359
Withdrew: Death115
Withdrew: Physician decision20
Withdrew: Did not receive drug52
Withdrew: Disease progression per pi5867
Withdrew: Data unavailable10
Withdrew: Withdrawal by subject913

Outcome measures

PrimaryProgression-Free Survival (PFS)

The duration of Progression-Free Survival (PFS) using progression events as determined by Independent Review Committee (IRC) per mRECIST, or death due to any cause. The analysis was conducted after at least 315 subjects were randomized and at least 138 events were observed.

Time frame:
Treatment period consisted of 4-week cycles with radiologic tumor assessment every 12 weeks from date of randomization until date of first documented PD or date of death from any cause, whichever came first, assessed up to 34 months.
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsXL184 (Cabozantinib)Placebo
Progression-Free Survival (PFS)11.2 (9.3 to 13.7)4.0 (3.0 to 5.4)
SecondaryOverall Survival (OS) With XL184 Compared With Placebo

Duration of Overall Survival (OS) from the time of randomization to death due to any cause. A Kaplan-Meier analysis was performed to estimate the median.

Time frame:
The pre-specified interim analysis of Overall Survival (OS) was assessed at 44% of required events. Includes data up to 15June2011. As of this date, the number of deaths required to conduct the primary analysis had not been reached.
Reported as:
Median · months
Overall Survival (OS) With XL184 Compared With Placebo
monthsXL184 (Cabozantinib)Placebo
Overall Survival (OS) With XL184 Compared With Placebo21.1 (16.59 to 28.52)NA (17.41 to NA)
SecondaryObjective Response Rate (ORR)

The proportion of subjects with a best overall response (BOR) of confirmed complete response (CR) or partial response (PR) as determined by the Independent Review Committee (IRC.) Per Response Evaluation Criteria in Solid Tumor Criteria (mRECIST v1.0) for target lesions and assessed by MRI or CT: Complete Response (CR) disappearance of all target lesions; Partial Response (PR) ≥ 30% decrease in the sum of the longest diameter of target lesions; Progressive Disease (PD) ≥ 20% increase in the sum of the longest diameter of target lesions. Overall Response Rate: ORR=CR +PR

Time frame:
Assessed at the same time as primary analysis of Progression Free Survival (PFS) data. Assessed at baseline and every 12 weeks until Progressive Disease (PD) up to 34 months.
Reported as:
Number · % of participants
Objective Response Rate (ORR)
% of participantsXL184 (Cabozantinib)Placebo
Objective Response Rate (ORR)28 (21.9 to 34.5)0 (0 to 0)
SecondaryDuration of Objective Response (OR): Independent Radiology Committee (IRC) Determined

For those subjects with Independent Radiology Committee (IRC) determined Objective Response Rate (ORR), the amount of time from documentation of Objective Response (OR) until Progressive Disease (PD) by mRECIST or death due to any cause.

Time frame:
From time of first documentation of Objective Response (OR), confirmed at a later visit ≥28 days later as Progressive Disease (PD) as defined by mRECIST or death due to any cause, assessed up to 34 months.
Reported as:
Median · months
Duration of Objective Response (OR): Independent Radiology Committee (IRC) Determined
monthsXL184 (Cabozantinib)Placebo
Duration of Objective Response (OR): Independent Radiology Committee (IRC) Determined14.6 (11.1 to 17.5)—
SecondaryBiochemical Response Calcitonin (CTN) %

For each on-treatment tumor marker assessment from each subject, the biochemical response of CTN was determined based on percent increase or decrease from baseline. Best biochemical response over course of treatment was determined from evaluation of subject's time point response data. Biochemical response criteria: Complete Response (CR) - decrease in tumor marker into normal range from baseline value; Partial Response (PR) - decrease of \>50% from baseline value when baseline value is above normal range; Stable Disease (SD) - no more than a 50% increase and no more than a 50% decrease from baseline value above normal range; Progressive Disease (PD) - increase of \>50% from baseline value when baseline value is above normal range / or increase from low or normal range at baseline to above normal range; Not Evaluable (NE) - missing baseline value / or baseline value is not elevated and response is not PD / or response can not be determined due to change in assay format.

Time frame:
Serum tumor markers CTN evaluated from blood samples collected at screening and every 12 weeks (±5 days from randomization) until date of first documented progression or date of death from any cause, whichever came first, assessed for up to 34 months.
Reported as:
Number · % participants
Biochemical Response Calcitonin (CTN) %
% participantsXL184 (Cabozantinib)Placebo
Biochemical Response Calcitonin (CTN) %22.6 ± 60.710.9 ± 115.4
SecondaryBiochemical Response Carcinoembryonic Antigen (CEA) %

For each on-treatment tumor marker assessment from each subject, the biochemical response of CEA was determined based on percent increase or decrease from baseline. Best biochemical response over the course of treatment was determined from evaluation of each subject's time point response data. Biochemical response: Complete Response (CR)- Decrease in tumor marker into normal range from baseline value; Partial Response (PR)- Decrease of \>50% from baseline value when baseline value is above normal range; Stable Disease (SD)- No more than a 50% increase and no more than a 50% decrease from baseline value above normal range; Progressive Disease (PD)- Increase of \>50% from baseline value when baseline value is above normal range / or increase from low or normal range at baseline to above normal range; Not Evaluable (NE)- Missing baseline value / or baseline value is not elevated and response is not Progressive Disease (PD) / or response can not be determined due to change in assay format.

Time frame:
Serum tumor markers CEA evaluated from blood samples collected at screening and every 12 weeks (± 5 days from randomization) until date of first documented progression or date of death from any cause, whichever came first, assessed for up to 34 months.
Reported as:
Number · % of participants
Biochemical Response Carcinoembryonic Antigen (CEA) %
% of participantsXL184 (Cabozantinib)Placebo
Biochemical Response Carcinoembryonic Antigen (CEA) %21.6 ± 58.210.9 ± 182.6

Adverse events

Collected over From baseline at regular intervals through to the date of the primary analysis. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
XL184 (Cabozantinib)—90/214 (42.1%)213/214 (99.5%)
Placebo—25/109 (22.9%)102/109 (93.6%)
Most frequent serious events
Showing 10 of 160
Most frequent serious events
EventXL184 (Cabozantinib)Placebo
DyspnoeaRespiratory, thoracic and mediastinal disorders2/2146/109
PneumoniaInfections and infestations7/2143/109
Mucosal inflammationGeneral disorders6/2140/109
HypocalcaemiaMetabolism and nutrition disorders6/2140/109
DysphagiaGastrointestinal disorders5/2142/109
DehydrationMetabolism and nutrition disorders5/2141/109
Pulmonary embolismRespiratory, thoracic and mediastinal disorders5/2140/109
HypertensionVascular disorders5/2140/109
VomitingGastrointestinal disorders4/2141/109
FatigueGeneral disorders4/2141/109
Most frequent other events
Showing 10 of 74
Most frequent other events
EventXL184 (Cabozantinib)Placebo
DiarrhoeaGastrointestinal disorders135/21436/109
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders105/2142/109
Weight decreasedInvestigations102/21411/109
Decreased appetiteMetabolism and nutrition disorders98/21417/109
NauseaGastrointestinal disorders92/21423/109
FatigueGeneral disorders86/21431/109
DysgeusiaNervous system disorders73/2146/109
Hair colour changesSkin and subcutaneous tissue disorders72/2141/109
StomatitisGastrointestinal disorders62/2143/109
HypertensionVascular disorders62/2144/109

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)XL184 (Cabozantinib)PlaceboTotal
<=18 years000
Between 18 and 65 years17286258
>=65 years472572
Age, Continuous
Age, Continuous(years)XL184 (Cabozantinib)PlaceboTotal
Mean54.4 ± 13.3353.8 ± 13.3954.2 ± 13.33
Sex: Female, Male
Sex: Female, Male(Participants)XL184 (Cabozantinib)PlaceboTotal
Female6841109
Male15170221
Region of Enrollment
Region of Enrollment(participants)XL184 (Cabozantinib)PlaceboTotal
Austria819
Belgium7512
Brazil437
Canada628
Chile011
Denmark101
France25530
Germany151025
Greece123
Portugal011
India516
Israel549
Italy281442
Korea, Republic of347
Netherlands538
Peru101
Poland12315
Russian Federation8513
Spain538
Switzerland101
Sweden6410
United Kingdom10919
United States633194
08

Study locations

114 sites
  • University of Alabama at Birmingham, Comprehensive Cancer Center
    Birmingham, Alabama 35294, United States
  • TGEN Clinical Research Service at Scottsdale Healthcare
    Scottsdale, Arizona 85258, United States
  • University of Arkansas for Medical Sciences
    Little Rock, Arkansas 72205, United States
  • Burbank, California 91505, United States
  • UCLA
    Los Angeles, California 90095, United States
  • Stanford Cancer Center
    Stanford, California 94305, United States
  • University of Colorado Cancer Center
    Aurora, Colorado 80045, United States
  • Yale University, School of Medicine
    New Haven, Connecticut 06520, United States
  • Washington Cancer Institute
    Washington, District of Columbia 20010, United States
  • H. Lee Moffet Cancer Center and Research Institute
    Tampa, Florida 33612, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Indiana University Melvin and Bren Simon Cancer Center
    Indianapolis, Indiana 46202, United States
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • Kansas University Medical Center
    Kansas City, Kansas 66160, United States
  • Johns Hopkins University
    Baltimore, Maryland 21287, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Capitol Comprehensive Cancer Care Clinic and Research Institute
    Jefferson City, Missouri 65109, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Nebraska Methodist Hospital
    Omaha, Nebraska 68114, United States
  • Ohio State University, James Cancer Hospital
    Columbus, Ohio 43210, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • St. Luke's Hospital & Health Network
    Bethlehem, Pennsylvania 18015, United States
  • Hospital of the University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Hollings Cancer Center
    Charleston, South Carolina 29425, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Vermont Cancer Center at Fletcher Allen Health Care
    Burlington, Vermont 05401, United States
  • Peninsula Cancer Institute
    Newport News, Virginia 23601, United States
  • Klagenfurt, Austria
  • Multiple site locations
    Wien, Austria
  • Cliniques Universitaires St. Luc
    Brussels, Belgium
  • Universitair Ziekenhuis
    Leuven, Belgium
  • Brasilia, Brazil
  • Lajeado, Brazil
  • Porto Alegre, Brazil
  • Multiple site locations
    Sao Paulo, Brazil
  • Calgary, Alberta, Canada
  • Toronto, Ontario, Canada
  • CHUM - Hopital Saint-Luc
    Montreal, Quebec, Canada
  • Sherbrooke, Quebec, Canada
  • Santiago, Chile
  • Odense, Denmark
  • Angers, France
  • Bordeaux, France
  • Lyon, France
  • Marseille, France
  • Reims, France
  • Villejuif, France
  • Klinik fuer Nuklearmedizin des Universitaetsklinikums Essen
    Essen, Germany
  • Gemeinschaftspraxis
    Heidelberg, Germany
  • Universitaetsklinikum Leipzig
    Leipzig, Germany
  • Johannes-Gutenberg Universitaet Mainz
    Mainz, Germany
  • Klinikum der Ludwig-Maximilians-Universitaet Muenchen
    Muenchen, Germany
  • Ludwig-Maximilians-Universitaet Muenchen
    Muenchen, Germany
  • Universitaetsklinikum Tuebingen
    Tuebingen, Germany
  • Universitaetsklinikum Wuerzburg
    Wuerzburg, Germany
  • Athens, Greece
  • Kidwai Institute of Oncology
    Bangalore, India
  • Indo-American Cancer Institute and Research Center
    Hyderabad, India
  • SEAROC Cancer Institute, S.K. Soni Hospital
    Jaipur, India
  • Netaji Subhash Chandra Bose Cancer Hospital Research Institute
    Kolkata, India
  • Central India Cancer Research Institute
    Nagpur, India
  • Shatabdi Superspeciality Hospital
    Nashik, India
  • All India Institute of Medical Sciences
    New Dehli, India
  • Deenanath Mangeshkar Hospital & Research Center
    Pune, India
  • Ruby Hall Clinic
    Pune, India
  • Haifa, Israel
  • Jerusalem, Israel
  • Petach Tikva, Israel
  • Tel Aviv, Israel
  • Florence, Italy
  • Milan, Italy
  • Naples, Italy
  • Pisa, Italy
  • Rome, Italy
  • Siena, Italy
  • Turin, Italy
  • Multiple site locations
    Seoul, Korea, Republic of
  • Amsterdam, Netherlands
  • Groningen, Netherlands
  • Leiden, Netherlands
  • Multiple site locations
    Lima, Peru
  • Bydgoszcz, Poland
  • Gliwice, Poland
  • Pozan, Poland
  • Szczecin, Poland
  • Warszawa, Poland
  • Coimbra, Portugal
  • Oporto, Portugal
  • Porto, Portugal
  • Obninsk, Russian Federation
  • Ufa, Russian Federation
  • Voronezh, Russian Federation
  • Yaroslavl, Russian Federation
  • Riyadh, Saudi Arabia
  • Multiple site locations
    Barcelona, Spain
  • Madrid, Spain
  • Murcia, Spain
  • Santiago de Compostela, Spain

Showing the first 100 of 114 sites across 24 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Schlumberger M, Elisei R, Muller S, Schoffski P, Brose M, Shah M, Licitra L, Krajewska J, Kreissl MC, Niederle B, Cohen EEW, Wirth L, Ali H, Clary DO, Yaron Y, Mangeshkar M, Ball D, Nelkin B, Sherman S. Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. Ann Oncol. 2017 Nov 1;28(11):2813-2819. doi: 10.1093/annonc/mdx479. PubMed 29045520 ↗
  • Elisei R, Schlumberger MJ, Muller SP, Schoffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle B, Cohen EE, Wirth LJ, Ali H, Hessel C, Yaron Y, Ball D, Nelkin B, Sherman SI. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013 Oct 10;31(29):3639-46. doi: 10.1200/JCO.2012.48.4659. Epub 2013 Sep 3. Erratum In: J Clin Oncol. 2014 Jun 10;32(17):1864. PubMed 24002501 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2008, a primary completion of Oct 2011 and a completion of Sep 2020. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2014, 2 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2008
First posted
Jun 25, 2008
Start
Jun 2008
Primary completionActual
Oct 2011
CompletionActual
Sep 2020
Results first posted
Sep 9, 2014
Last update
Apr 20, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00704730
Lead sponsor
Exelixis
Responsible party
Sponsor
First posted
Jun 25, 2008
Start date
Jun 2008
Primary completion
Oct 2011
Completion
Sep 2020
Results posted
Sep 9, 2014
Last update
Apr 20, 2021

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabozantinib

Start the discussion